Table 2.
Central antinociceptive activity of naproxen and its metal chelates at different time intervals.
| Group | Dose (mg/kg) | Reaction time (sec) | ||
|---|---|---|---|---|
| 30 min (% elongation) |
60 min (% elongation) |
90 min (% elongation) |
||
| Control | — | 6.38 ± 0.34 | 5.86 ± 0.46 | 6.12 ± 0.23 |
| Morphine | 02 | 18.6 ± 0.59∗
(191.54) |
15.86 ± 0.28∗
(170.65) |
13.06 ± 0.72∗
(113.40) |
| Naproxen | 25 | 9.97 ± 0.52∗
(56.27) |
11.06 ± 0.45∗
(88.74) |
10.46 ± 0.70∗
(70.92) |
| Naproxen | 50 | 12.12 ± 0.62∗
(89.97) |
11.94 ± 0.80∗
(103.75) |
13.3 ± 0.42∗
(117.32) |
| Naproxen-copper complex | 25 | 10.8 ± 0.33∗
(69.28) |
10.8 ± 0.44∗
(84.30) |
12.4 ± 0.34∗
(102.61) |
| Naproxen-copper complex | 50 | 14.62 ± 0.42∗
(129.15) |
14.8 ± 0.35∗
(152.56) |
14.52 ± 0.49∗
(137.25) |
| Naproxen-cobalt complex | 25 | 11.02 ± 0.48∗
(72.73) |
11.32 ± 0.53∗
(93.17) |
11.96 ± 0.50∗
(95.42) |
| Naproxen-cobalt complex | 50 | 13.38 ± 0.34∗
(109.72) |
15.3 ± 0.86∗
(161.09) |
14.86 ± 0.44∗
(142.81) |
| Naproxen-iron complex | 25 | 9.84 ± 0.79∗
(54.23) |
10.78 ± 0.61∗
(83.96) |
11.04 ± 0.52∗
(80.39) |
| Naproxen-iron complex | 50 | 13.5 ± 0.84∗
(111.60) |
13.64 ± 0.69∗
(132.76) |
12.74 ± 0.87∗
(108.17) |
| Naproxen-silver complex | 25 | 10.84 ± 0.55∗
(69.91) |
11.06 ± 0.61∗
(88.74) |
12.32 ± 0.45∗
(101.31) |
| Naproxen-silver complex | 50 | 13.8 ± 0.58∗
(116.30) |
14.18 ± 0.45∗
(141.98) |
13.6 ± 0.42∗
(122.22) |
| Naproxen-zinc complex | 25 | 12.48 ± 0.29∗
(95.61) |
12.86 ± 0.51∗
(119.45) |
12.18 ± 0.54∗
(99.02) |
| Naproxen-zinc complex | 50 | 15.38 ± 0.45∗
(141.07) |
15.44 ± 0.47∗
(163.48) |
15.12 ± 0.31∗
(147.06) |
Each value represents the mean ± SEM (n = 5). ∗ P < 0.001 was considered significant compared with control.